Skip to Content

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新,请点击此处查看详情。

Merck
CN

Long term myriocin treatment increases MRP1 transport activity.

The international journal of biochemistry & cell biology (2012-11-28)
Peter Meszaros, Karin Klappe, Annie van Dam, Pavlina T Ivanova, Stephen B Milne, David S Myers, H Alex Brown, Hjalmar Permentier, Dick Hoekstra, Jan W Kok
ABSTRACT

We investigated the effect of myriocin treatment, which extensively depletes sphingolipids from cells, on multidrug resistance-related protein 1 (MRP1) efflux activity in MRP1 expressing cells and isolated plasma membrane vesicles. Our data reveal that both short term (3 days) and long term (7 days) treatment effectively reduce the cellular sphingolipid content to the same level. Intriguingly, a two-fold increase in MRP1-mediated efflux activity was observed following long term treatment, while short term treatment had no impact. Very similar data were obtained with plasma membrane vesicles isolated from myriocin-treated cells. Exploiting the cell-free vesicle system, Michaelis-Menten analysis revealed that the intrinsic MRP1 activity remained unaltered; however, the fraction of active transporter molecules increased. We demonstrate that the latter effect is due to an enhanced recruitment of MRP1 into lipid raft fractions, thereby promoting MRP1 activity.

MATERIALS
Product Number
Brand
Product Description

Avanti
20:4 PE, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, chloroform
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 mg
Available to ship on April 21, 2025
Details...
CN¥637.23
1 g
Available to ship on April 21, 2025
Details...
CN¥3,939.96